TCM Biotech International Corp.(TW:4169)
NT$116.50-4.00 (-3.32%)
TW:4169
TCM Biotech International Corp. financials statements
NT$116.50
At close:-4.00 (-3.32%)
TCM Biotech International Corp. (4169) Ratios
TCM Biotech International Corp. Ratios
TW:4169's free cash flow for Q2 2026 was NT$-47.32M. For the 2026 fiscal year, TW:4169's free cash flow was decreased by NT$-3.55M and operating cash flow was NT$-43.77M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.47 | 9.91 | 4.95 | 2.28 | 2.67 |
| Quick Ratio | 6.26 | 8.34 | 3.90 | 1.51 | 1.61 |
| Cash Ratio | 2.13 | 2.84 | 2.54 | 0.40 | 0.33 |
| Solvency Ratio | 0.29 | 0.36 | 0.15 | 0.12 | 0.07 |
| Operating Cash Flow Ratio | 0.34 | 2.04 | -0.19 | 0.23 | 0.09 |
| Short-Term Operating Cash Flow Coverage | 2.98 | 15.76 | -0.66 | 0.77 | 0.26 |
| Net Current Asset Value | NT$ 709.60M | NT$ 688.70M | NT$ 713.27M | NT$ 187.54M | NT$ 168.27M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.04 | 0.09 | 0.20 | 0.20 |
| Debt-to-Equity Ratio | 0.04 | 0.05 | 0.12 | 0.32 | 0.32 |
| Debt-to-Capital Ratio | 0.04 | 0.05 | 0.10 | 0.24 | 0.24 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.03 | 0.05 | 0.15 | 0.17 |
| Financial Leverage Ratio | 1.14 | 1.12 | 1.25 | 1.61 | 1.58 |
| Debt Service Coverage Ratio | 2.80 | 3.80 | 0.72 | 0.58 | 0.36 |
| Interest Coverage Ratio | 21.59 | 6.23 | 8.06 | 10.61 | 1.08 |
| Debt to Market Cap | 0.00 | 0.01 | 0.04 | 0.11 | 0.09 |
| Interest Debt Per Share | 0.74 | 0.89 | 2.38 | 3.54 | 3.31 |
| Net Debt to EBITDA | -4.79 | -3.60 | -8.15 | 1.79 | 4.83 |
| Profitability Margins | |||||
| Gross Profit Margin | 43.28% | 49.11% | 49.52% | 55.89% | 51.10% |
| EBIT Margin | 2.72% | 3.99% | 2.56% | 3.18% | 0.60% |
| EBITDA Margin | 6.15% | 7.58% | 4.82% | 5.67% | 3.17% |
| Operating Profit Margin | 2.72% | 1.50% | 2.30% | 3.15% | 0.30% |
| Pretax Profit Margin | 3.25% | 3.75% | 2.27% | 2.88% | 0.32% |
| Net Profit Margin | 2.80% | 3.15% | 1.92% | 2.28% | 0.27% |
| Continuous Operations Profit Margin | 2.80% | 3.15% | 1.92% | 2.28% | 0.27% |
| Net Income Per EBT | 85.97% | 83.98% | 84.30% | 78.98% | 82.99% |
| EBT Per EBIT | 119.53% | 250.04% | 98.67% | 91.40% | 105.91% |
| Return on Assets (ROA) | 1.59% | 1.78% | 1.40% | 2.12% | 0.23% |
| Return on Equity (ROE) | 1.82% | 1.98% | 1.76% | 3.40% | 0.36% |
| Return on Capital Employed (ROCE) | 1.71% | 0.91% | 1.99% | 3.97% | 0.33% |
| Return on Invested Capital (ROIC) | 1.45% | 0.75% | 1.59% | 2.82% | 0.25% |
| Return on Tangible Assets | 1.62% | 1.81% | 1.43% | 2.18% | 0.24% |
| Earnings Yield | 0.19% | 0.61% | 0.60% | 1.27% | 0.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.52 | 4.71 | 3.74 | 3.49 | 3.68 |
| Payables Turnover | 9.12 | 25.87 | 8.67 | 4.71 | 6.78 |
| Inventory Turnover | 2.80 | 2.63 | 2.35 | 2.02 | 1.84 |
| Fixed Asset Turnover | 2.44 | 2.28 | 3.30 | 2.66 | 2.46 |
| Asset Turnover | 0.57 | 0.56 | 0.73 | 0.93 | 0.86 |
| Working Capital Turnover Ratio | 0.93 | 0.88 | 1.81 | 2.75 | 2.31 |
| Cash Conversion Cycle | 171.19 | 202.19 | 210.82 | 207.59 | 243.37 |
| Days of Sales Outstanding | 80.67 | 77.57 | 97.53 | 104.52 | 99.15 |
| Days of Inventory Outstanding | 130.57 | 138.73 | 155.38 | 180.55 | 198.08 |
| Days of Payables Outstanding | 40.04 | 14.11 | 42.08 | 77.47 | 53.86 |
| Operating Cycle | 211.23 | 216.30 | 252.91 | 285.07 | 297.23 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.66 | 2.84 | -0.71 | 1.07 | 0.30 |
| Free Cash Flow Per Share | 0.62 | 2.69 | -0.80 | 0.96 | 0.15 |
| Dividend Paid and CapEx Coverage Ratio | 1.68 | 6.65 | -5.75 | 9.88 | 0.62 |
| Capital Expenditure Coverage Ratio | 15.68 | 20.04 | -7.64 | 9.88 | 1.99 |
| Operating Cash Flow Coverage Ratio | 0.91 | 3.28 | -0.30 | 0.31 | 0.09 |
| Operating Cash Flow to Sales Ratio | 0.06 | 0.25 | -0.04 | 0.07 | 0.02 |
| Free Cash Flow Yield | 0.36% | 4.65% | -1.38% | 3.26% | 0.42% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 535.94 | 160.83 | 166.00 | 79.38 | 968.28 |
| Price-to-Sales (P/S) Ratio | 14.77 | 5.13 | 3.18 | 1.80 | 2.60 |
| Price-to-Book (P/B) Ratio | 9.60 | 3.23 | 2.92 | 2.68 | 3.53 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 277.43 | 21.49 | -72.61 | 30.68 | 240.08 |
| Price-to-Operating Cash Flow Ratio | 259.74 | 20.42 | -82.11 | 27.58 | 119.24 |
| Price-to-Earnings Growth (PEG) Ratio | -48.23 | 56.29 | -30.71 | 0.09 | -10.44 |
| Enterprise Value Multiple | 235.29 | 64.11 | 57.85 | 33.44 | 86.86 |
| Enterprise Value | 9.92B | 3.24B | 2.70B | 1.52B | 1.94B |
| EV to EBITDA | 235.29 | 64.11 | 57.85 | 33.44 | 86.86 |
| EV to Sales | 14.48 | 4.86 | 2.79 | 1.90 | 2.76 |
| EV to Free Cash Flow | 271.90 | 20.35 | -63.64 | 32.41 | 254.22 |
| EV to Operating Cash Flow | 254.56 | 19.33 | -71.97 | 29.13 | 126.27 |
| Tangible Book Value Per Share | 17.57 | 17.58 | 19.44 | 10.41 | 9.63 |
| Shareholders’ Equity Per Share | 17.87 | 17.94 | 19.89 | 10.94 | 10.21 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.14 | 0.16 | 0.16 | 0.21 | 0.17 |
| Revenue Per Share | 11.61 | 11.29 | 18.28 | 16.36 | 13.84 |
| Net Income Per Share | 0.32 | 0.36 | 0.35 | 0.37 | 0.04 |
| Tax Burden | 0.86 | 0.84 | 0.84 | 0.79 | 0.83 |
| Interest Burden | 1.20 | 0.94 | 0.89 | 0.91 | 0.53 |
| Research & Development to Revenue | 0.13 | 0.14 | 0.08 | 0.10 | 0.11 |
| SG&A to Revenue | 0.28 | 0.34 | 0.39 | 0.42 | 0.39 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.03 | 6.69 | -2.02 | 2.86 | 8.18 |
Currency in TWD
